한글목차

이 보고서는 세계 색전입자(Embolization Particle) 시장을 조사 분석하여 시장 역학, 지역 및 부문 분석, 기업 프로파일 등을 제공합니다.

목차

제1장 보고서 프롤로그

제2장 시장 서론

제3장 조사 방법

제4장 시장 역학

• 서론
• 성장 촉진요인
• 성장 억제요인
• 기회
• 메가트렌드
• 거시경제 지표

제5장 시장 요인 분석

• Porter의 Five Forces 분석
• 밸류체인 분석
  • 연구개발
  • 임상시험 및 법적 문제
  • 제조
  • 마케팅 및 판매
• 구매 활동, 전략, 영향
• 투자 기회 분석
• 색전입자(LIPIODOL) 가격에 대한 영향 : 효과와 영향
• 색전술의 상환 문제

제6장 세계의 색전입자 시장 : 제품 유형별

• 서론
• RADIOEMBOLIZATION SPHERES
• DRUG ELUTING BEADS

제7장 세계의 색전입자 시장 : 용도별

• 서론
• 종양
• 비뇨기
• 말초혈관 질환
• 신경

제8장 세계의 색전입자 시장 : 폐쇄 레벨별

• 서론
  • 근위
  • 원위

제9장 세계의 색전입자 시장 : 최종사용자별

• 서론
• 병원 및 진료소
• 외래센터

제10장 세계의 색전입자 시장 : 지역별

• 서론
• 아메리카
  • 미국
  • 캐나다
  • 남미
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 기타 아시아태평양
  • 중동 및 아프리카

제11장 경쟁 구도

• 서론
• 기업 점유율 분석

제12장 기업 개요

• BOSTON SCIENTIFIC CORPORATION
• GUERBET
• BTG INTERNATIONAL LTD
• MEDTRONICS
• SIRTEX
• TERUMO
• MERIT MEDICAL

제13장 MRFR 결론

• 주요 조사 결과
  • CEO의 관점
  • 미충족 요구
• 주목해야 할 주요 기업

제14장 부록

영문목차

Market Overview

A non-invasive therapy known as embolisation, the Endovascular Particle is a cutting-edge concept that intends to halt not only hemorrhage but also ways to stop blood circulation to a tumour in a logical order to diminish it or in readiness for total abolition. Few embolised particles or tiny materials are forcefully injected into the clinic's patients' critical veins during the advanced process known as embolisation particle in order to entirely block or stop the blood flow to conventional cancerous cells. A very small percentage of individuals who have pre-existing tumours that current surgery cannot entirely remove have the option of embolisation. Tumors that are too large to be cured with current ablation techniques can be treated with embolisation particles. Ablation can also use embolisation particles. Embolization does, without a doubt, limit some of the blood flow to the healthy liver tissue that is present inside the body, thus it might not be a good alternative for some people whose livers have been damaged by diseases like serious hepatitis- or cirrhosis-related disorders. A significant part of contemporary interventional radiology uses embolisation particles in a variety of treatments.

Segment Overview

Insights into various market segments, including Structure, Application, and Region, can be found in the global embolisation particle market. The degree of occlusion, contemporary application, end-user, and numerous product kinds are used to segment the global market.

Research organisations, traders, importers, exporters, suppliers, and industry end users are the main market participants. The idea is picking up steam. The businesses are concentrating more on enhancing their methods for product innovation.

Many embolisation particle markets are being broken down and researched regionally, including those in Europe, Asia Pacific, North America, and the rest of the world.

Regional Analysis

Without a question, North America is the market leader because to the significant presence of international competitors in this area and the rapid improvement of technology. Geography predicts that North America will account for the largest share of profits owing to the increased use of various cloud-based services by means of manufacturing systems and various distribution channels. In addition, the market for the Asia Pacific region is expected to expand quickly due to increased investment.

Major Players

Market industry participants include: Medtronics, GuerbetTerumoBTG International Ltd. Sirtex, Boston Scientific Corporation, and Merit Medical.

COVID 19 Impacts

The market analysis for embolisation particles and 215 other nations have both been impacted by COVID 19. Countries have implemented lockdowns to address the harmful consequences, which has hurt the market for embolisation particles. The epidemic presents the industry with a number of difficulties because it has an international impact. Many elements, including supply chain risk, distribution issues, a lack of workforce workers, and drastically reduced development activities, have had a major impact on current demand and supply. Consumers are not as engaged as they once were. There are significant strategic developments going on. Due to the rising demand from customers all over the world, MNCs are spending more in the market for embolisation particles.

TABLE OF CONTENTS

1 REPORT PROLOGUE

2 MARKET INTRODUCTION

• 2.1 DEFINITION 15
• 2.2 SCOPE OF THE STUDY 15
  • 2.2.1 RESEARCH OBJECTIVE 15
  • 2.2.2 ASSUMPTIONS 15
  • 2.2.3 LIMITATIONS 16

3 RESEARCH METHODOLOGY

• 3.1 PRIMARY RESEARCH METHODOLOGY 18
• 3.2 SECONDARY RESEARCH METHODOLOGY 19
• 3.3 MARKET SIZE ESTIMATION 20
• 3.4 MARKET SHARE ANALYSIS 22
• 3.5 TRADE ANALYSIS 22
• 3.6 MARKET PRICING APPROACH 22

4 MARKET DYNAMICS

• 4.1 INTRODUCTION 23
• 4.2 DRIVER 24
  • 4.2.1 GROWING DEMAND OF EMBOLIZATION PARTICLES FOR INTERVENTIONAL RADIOLOGY AND INTERVENTIONAL CARDIOVASCULAR PROCEDURE (IMPACT WEIGHTAGE- 35%) 24
  • 4.2.2 EMBOLIZATION IS BEST MINIMALLY INVASIVE ALTERNATIVES AVAILABLE FOR THE

INTERVENTIONAL PROCEDURES (IMPACT WEIGHTAGE- 30%) 25

• 4.2.3 INCREASING PREVALENCE OF VARIOUS TYPES OF CANCER IS ONE OF THE MAJOR FACTOR RESPONSIBLE FOR MARKET GROWTH (IMPACT WEIGHTAGE- 25%) 26
• 4.2.4 FAVOURABLE REIMBURSEMENT SCENARIO (IMPACT WEIGHTAGE- 10%) 27
• 4.3 RESTRAINTS 28
  • 4.3.1 LESS NUMBER OF INTERVENTIONAL NEURORADIOLOGISTS AND INTERVENTIONAL

NEURORADIOLOGY (INR) LABS (IMPACT WEIGHTAGE- 40%) 28

• 4.3.2 STRICT REGULATORY RULES (IMPACT WEIGHTAGE-60% 29
• 4.4 OPPORTUNITIES 30
  • 4.4.1 RECENT ADVANCES IN MICROSPHERE TECHNOLOGIES 30
• 4.5 MEGA TRENDS 30
• 4.6 MACROECONOMIC INDICATORS 31

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S 5 FORCES ANALYSIS 32
  • 5.1.1 BARGAINING POWER OF SUPPLIERS 33
  • 5.1.2 BARGAINING POWER OF BUYERS 33
  • 5.1.3 THREAT OF NEW ENTRANTS 33
  • 5.1.4 THREAT OF SUBSTITUTES 33
  • 5.1.5 INTENSITY OF RIVALRY 33
• 5.2 VALUE CHAIN ANALYSIS 34
  • 5.2.1 R&D 34
  • 5.2.2 CLINICAL TEST & LEGAL ISSUES 35
  • 5.2.3 MANUFACTURING 35
  • 5.2.4 MARKETING & SALES 35
• 5.3 PURCHASING ACTIVITIES, STRATEGIES AND IMPLICATIONS 36
• 5.4 INVESTMENT OPPORTUNITY ANALYSIS 36
• 5.5 PRICING IMPACT OF EMBOLIZATION PARTICLE (LIPIODOL): EFFECTS & IMPLICATIONS 37
• 5.6 REIMBURSEMENT ISSUES IN EMBOLIZATION PROCEDURES 38

6 GLOBAL EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE

• 6.1 INTRODUCTION 40
• 6.2 RADIOEMBOLIZATION SPHERES 41
• 6.3 DRUG ELUTING BEADS 42

7 GLOBAL EMBOLIZATION PARTICLE MARKET, BY APPLICATION

• 7.1 INTRODUCTION 43
• 7.2 ONCOLOGY 45
• 7.3 UROLOGY 46
• 7.4 PERIPHERAL VASCULAR DISEASE 47
• 7.5 NEUROLOGY 48

8 GLOBAL EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION

• 8.1 INTRODUCTION 49
  • 8.1.1 PROXIMAL 50
  • 8.1.2 DISTAL 50

9 GLOBAL EMBOLIZATION PARTICLE MARKET, BY END USER

• 9.1 INTRODUCTION 51
• 9.2 HOSPITALS & CLINICS 52
• 9.3 AMBULATORY CENTERS 53

10 GLOBAL EMBOLIZATION PARTICLE MARKET, BY REGION

• 10.1 INTRODUCTION 54
• 10.2 AMERICAS 56
  • 10.2.1 U.S. 59
  • 10.2.2 CANADA 61
  • 10.2.3 SOUTH AMERICA 63
• 10.3 EUROPE 66
  • 10.3.1 GERMANY 69
  • 10.3.2 FRANCE 71
  • 10.3.3 UK 73
  • 10.3.4 ITALY 75
  • 10.3.5 SPAIN 77
  • 10.3.6 REST OF EUROPE 79
• 10.4 ASIA PACIFIC 82
  • 10.4.1 JAPAN 85
  • 10.4.2 CHINA 87
  • 10.4.3 INDIA 89
  • 10.4.4 REPUBLIC OF KOREA 91
  • 10.4.5 AUSTRALIA 93
  • 10.4.6 REST OF ASIA PACIFIC 95
  • 10.4.7 MIDDLE EAST & AFRICA 97

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION 100
• 11.2 COMPANY SHARE ANALYSIS 101

12 COMPANY PROFILES

• 12.1 BOSTON SCIENTIFIC CORPORATION 102
  • 12.1.1 COMPANY OVERVIEW 102
  • 12.1.2 FINANCIALS 102
  • 12.1.3 PRODUCTS 102
  • 12.1.4 STRATEGY 102
  • 12.1.5 KEY DEVELOPMENTS 102
• 12.2 GUERBET 103
  • 12.2.1 COMPANY OVERVIEW 103
  • 12.2.2 FINANCIALS 103
  • 12.2.3 PRODUCTS 103
  • 12.2.4 STRATEGY 103
  • 12.2.5 KEY DEVELOPMENTS 103
• 12.3 BTG INTERNATIONAL LTD 104
  • 12.3.1 COMPANY OVERVIEW 104
  • 12.3.2 FINANCIALS 104
  • 12.3.3 PRODUCTS 104
  • 12.3.4 STRATEGY 104
  • 12.3.5 KEY DEVELOPMENTS 104
• 12.4 MEDTRONICS 105
  • 12.4.1 COMPANY OVERVIEW 105
  • 12.4.2 FINANCIALS 105
  • 12.4.3 PRODUCTS 105
  • 12.4.4 STRATEGY 105
  • 12.4.5 KEY DEVELOPMENTS 105
• 12.5 SIRTEX 106
  • 12.5.1 COMPANY OVERVIEW 106
  • 12.5.2 FINANCIALS 106
  • 12.5.3 PRODUCTS 106
  • 12.5.4 STRATEGY 106
  • 12.5.5 KEY DEVELOPMENTS 106
• 12.6 TERUMO 107
  • 12.6.1 COMPANY OVERVIEW 107
  • 12.6.2 FINANCIALS 107
  • 12.6.3 PRODUCTS 107
  • 12.6.4 STRATEGY 107
  • 12.6.5 KEY DEVELOPMENTS 107
• 12.7 MERIT MEDICAL 108
  • 12.7.1 COMPANY OVERVIEW 108
  • 12.7.2 FINANCIALS 108
  • 12.7.3 PRODUCTS 108
  • 12.7.4 STRATEGY 108
  • 12.7.5 KEY DEVELOPMENTS 108

13 MRFR CONCLUSION

• 13.1 KEY FINDINGS 109
  • 13.1.1 FROM CEO'S VIEW POINT 109
  • 13.1.2 UNMET NEEDS 109
• 13.2 KEY COMPANIES TO WATCH 109

14 APPENDIX

• 14.1 DISCUSSION BLUE PRINT 110
• 14.2 REFERENCES 112